Welcome to our dedicated page for COGNEX SEC filings (Ticker: CGNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cognex Corporation filings document regulatory disclosures for an operating company focused on industrial machine vision products and automation technology. Its Form 8-K reports cover furnished operating results, quarterly cash dividends, share repurchase authorization, board and officer matters, annual meeting voting results, and changes in the company’s independent registered public accounting firm.
Proxy materials describe director elections, governance matters, executive compensation, shareholder voting procedures, and board committee oversight. The filing record also includes exhibit-based disclosures tied to financial-results releases and capital-return actions involving Cognex common stock.
COGNEX CORP CEO & President Matthew Moschner reported option-related trades in COGNEX CORP common stock on August 11, 2026. He exercised 16,600 stock options and sold 24,962 shares of common stock in open-market transactions. The option exercises and related sales were effected under a pre-arranged Rule 10b5-1 trading plan. Moschner continues to hold substantial unexercised stock options and restricted stock units expiring between 2031 and 2036.
A shareholder of Cognex Corporation is preparing to sell shares of the company’s common stock under a Rule 144 notice. The plan covers 16,600 shares to be issued and sold in connection with an exercise of stock options, dated 08/11/2026, and 8,362 shares related to restricted stock units dated 02/20/2025. Sales are indicated as cash transactions on NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services.
COGNEX CORP Vice President Darren Marc Long reported equity compensation activity involving restricted stock units and related common stock. On August 7, 2026, 2,500 restricted stock units were exercised into 2,500 shares of common stock at a conversion price of $0.00 per share. In connection with this vesting, 734 common shares were delivered or withheld at $66.89 per share to satisfy tax withholding obligations, while the remaining shares from the vesting event were retained.
The filing also lists ongoing direct holdings of multiple non-qualified stock options on Cognex common stock, with exercise prices ranging from $33.04 to $64.43 per share and expirations between 2032 and 2036, covering underlying share amounts such as 34,271 and 31,095. Additional unvested restricted stock units remain outstanding with scheduled vesting through 2029.
COGNEX CORP CEO and President Matthew Moschner reported equity compensation activity on August 7, 2026. 4,999 restricted stock units were exercised into the same number of common shares, with 2,218 shares withheld at $66.89 per share to satisfy tax withholding obligations. He continues to hold multiple non-qualified stock option grants and restricted stock units covering substantial additional shares of Cognex common stock.
Cognex delivered significantly stronger results in Q2 2026, with revenue of $291,263,000, up 17% year over year, and gross margin improving to 71% from 67%. Operating income rose to $85,517,000 (29% of revenue), and net income reached $72,756,000, or $0.43 per diluted share.
For the first half of 2026, revenue grew 20% to $559,700,000 and net income was $124,460,000, supported by broad-based demand, especially in Greater China and the Americas, while Europe was softer. Cognex held $755,013,000 in cash and investments with no long‑term debt, generated $114,246,000 of operating cash flow, repurchased 2,501,000 shares for $105,231,000, and paid dividends totaling $28,454,000 in six months.
Cognex Corporation reported a strong second quarter for the period ended July 5, 2026. Revenue reached a record $291 million, up 17% year over year (16% in constant currency), with operating income of $86 million and an operating margin of 29.4%. Adjusted EBITDA was $94 million, for a margin of 32.2%, while net income was $73 million and diluted EPS was $0.43; adjusted diluted EPS was $0.45, up 80% year over year.
Gross margin improved to 70.6%, and operating expenses declined 3% versus the prior year quarter, supporting the eighth consecutive quarter of margin expansion. Cognex ended the quarter with $755 million in cash and investments and no debt, generated $69 million in operating cash flow and $68 million in free cash flow, and paid $14 million in dividends.
The company issued guidance for third-quarter 2026 revenue of $300–$320 million and full-year 2026 revenue of $1.13–$1.15 billion, with higher adjusted EBITDA margins and adjusted EPS versus 2025. Cognex also declared a quarterly dividend of $0.085 per share and highlighted the general availability of its OneVision™ AI-powered machine vision platform.
CGNX files a Form 144 reporting proposed sales of common stock by an affiliate. The filing lists 172,667 shares to be sold on 06/30/2026 in connection with a stock option exercise for cash. The filing also discloses three sales by Robert J. Willett totaling listed share amounts within the prior three months.
CGNX files a Rule 144 notice reporting the intended sale of 8,576 shares of Common Stock via a stock option exercise on 06/29/2026.
The notice lists prior sales during the past three months: 53,726 shares sold on 05/06/2026 for $3,312,316.58 and 423,478 shares sold on 05/07/2026 for $28,831,493.28. The broker listed is Fidelity Brokerage Services LLC.
Cognex Corp vice president Darren Marc Long reported a combination of option exercises and share sales in company stock. On May 27, 2026, he exercised non-qualified stock options covering 18,673 shares of common stock at strike prices of $49.12, $51.49, and $56.44 per share.
On the same date, he completed open-market sales totaling 20,252 shares of common stock at prices of $66.5201 and $66.3215 per share. After these transactions, Long directly held 5,569 shares of Cognex common stock. The filing also lists prior grants of stock options and restricted stock units as part of his ongoing equity compensation.
Morgan Stanley Smith Barney LLC filed a Form 144 reporting the proposed sale of Common Stock of CGNX tied to a stock option exercise for 18,673 shares scheduled on 05/27/2026. The filing also lists prior restricted stock grants dated 02/16/2022, 02/16/2023, and 02/18/2023 with 145, 216, and 1,218 shares respectively.